Press Releases CSL Limited OTC Markets

Equities

CSLLY

US12637N2045

Market Closed - OTC Markets Other stock markets 20:56:42 26/06/2024 BST			5-day change	1st Jan Change
97.37 ^USD	-0.50%		+0.29%	+0.20%

06-25	Finland to start bird flu vaccinations for humans	RE
06-21	Mining, gold stocks lift Australian shares; c.bank's hawkish stance caps gains	RE

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CSL : Seqirus, a Proud Champion of Pandemic Preparedness, Signs an Agreement with the European Commission to Provide Pre-Pandemic Vaccines to the EU	06-11	PU
CSL : Seqirus and ARS Pharma sign agreement to commercialise neffy™ (adrenaline nasal spray) in Australia and New Zealand	04-30	PU
CSL : Shareholder Information Meetings	04-23	PU
Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build “Australia’s next CSL”	04-17	PU
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure	03-19	AQ
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy	02-26	AQ
CSL - Half year reported NPATA US$2 billion-1,-2 Up 13% at constant currency-3	02-14	AQ
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³	02-13	AQ
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112	02-12	AQ
CSL Limited - Notice of Investor, Analyst Briefing 2024 Half Year Result	01-31	AQ
CSL - Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options	01-17	AQ
CSL Behring Announces Availability of Hizentra 10g Prefilled Syringe	01-04	AQ
CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA 4-and 5-Gram Vials	01-03	AQ
CSL and Arcturus Therapeutics ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster	12-22	AQ
CSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older	12-21	AQ
CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance	12-15	AQ
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults	11-29	AQ
Iron Deficiency Day 2023, CSL Vifor calls for access to iron deficiency diagnosis and treatment	11-27	AQ
Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment	11-24	AQ
CSL and uniQure Win 2023 Prix Galien USA Award	30/10/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases CSL Limited OTC Markets

Equities

CSLLY

US12637N2045

Press Releases

Filters